Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

European Journal of Clinical Pharmacology

Volumn 62, Issue 8, 2006, Pages 597-603

  Shimizu, Mikiko ^a   Uno, Tsukasa ^a   Yasui Furukori, Norio ^a   Sugawara, Kazunobu ^b   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clarithromycin; CYP2C19; CYP3A4; Rabeprazole; Verapamil

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; RABEPRAZOLE; SULFIDE; VERAPAMIL;

ACID SECRETION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; VERAPAMIL;

EID: 33746446370     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0152-9     Document Type: Article

References (36)

1. Prakash A, Faulds D (1998) Rabeprazole. Drugs 55:261-267
2. Williams MP, Pounder RE (1999) Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 13:3-10
3. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28
4. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 13:27-36
5. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K et al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154
6. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton inhibitor. Pharmacogenetics 6:81-91
7. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y et al (2003) Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 26:386-390
8. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y et al (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15:793-803
9. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M et al (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937
10. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M et al (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
11. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, et al (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290-301
12. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y (2004) Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19:113-122
13. Uno T, Shimizu M, Yasui-Frukori N, Sugawara K, Tateishi T (2006) Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 61:309-314
14. Soll AH (1996) Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 275:622-629
15. Walsh JH, Peterson WL (1995) The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 333:984-991
16. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C et al (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1:138-144
17. Jurima-Romet M, Crawford K, Cyr T, Inaba T (1994) Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857
18. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N et al (1999) Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66:265-274
19. Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T (2005) Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302-309
20. Zhao XJ, Ishizaki T (1999) A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet 24:272-278
21. Ma B, Prueksaritanont T, Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125-130
22. Wang YH, Jones DR, Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266
23. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Review article: mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304
24. Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M et al (2000) Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 27:587-593
25. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R et al (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128
26. Rengelshausen J, Goggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J et al (2003) Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 56:32-38
27. Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y et al (2003) Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 37:178-181
28. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A et al (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-219
29. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I et al (2000) Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 11:1471-1476
30. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551-557
31. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
32. Uno T, Yasui-Furukori N, Shimizu M, Sugawara K, Tateishi T (2005) Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. J Chromatogr B 824:238-243
33. Center for Drug Evaluation and Research (2000) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD
34. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda et al (1995) Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 58:155-164
35. Miura M, Satoh S, Tada H, Habuchi T, Suzuki T (2006) Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol 62:113-117
36. Itagaki F, Homma M, Takara K, Ohnishi N, Yokoyama T, Sakaeda T et al (2004) Effect of rabeplazole on MDR1-mediated transport of rhodamine 123 in Caco-2 and Hvr 100-6 cells. Biol Pharm Bull 27:1694-1696